iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) has secured shareholder approval for two key amendments to the explanatory statement of its proposed preferential issue through a re-opened postal ballot process. The resolutions, which address a typographical error in share allocation and provide detailed post-issue capital disclosures, were passed with 100% of the valid votes cast. The voting process was conducted remotely from June 27, 2026, to June 29, 2026, following a corrigendum issued on June 26, 2026, to comply with BSE Limited queries under the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Corrections to Share Allocation

The first resolution approved the correction of a typographical error in the number of equity shares to be allotted to Dhairyasheel Vasantrao Yadav, Promoter & Director. The filing rectified the entry from "4,50,50" to 4,50,500 equity shares. His pre-issue shareholding stands at 11,15,000 shares. The underlying resolution for the preferential issue had already been passed by members on May 21, 2026, and this vote solely confirmed the disclosure amendments.

Post-Issue Capital Holdings

The second resolution replaced a general statement regarding post-preferential issue capital with a detailed person-wise disclosure. The percentage of post-preferential issue capital to be held by each allottee was disclosed, confirming that the existing promoters will continue to be the promoters of the company and that there will be no change in management or control.

Voting Results Summary

The re-opened e-voting process was managed by CS Anuj Gupta of M/s. Anuj Gupta & Associates. A total of 13 members participated, casting 553,230 valid votes in favour of both resolutions. No votes were cast against the resolutions. The detailed results are outlined below:

The company confirmed that the votes cast during the original e-voting window in April and May 2026 on the original Item No. 7 were cancelled, and only the votes from this re-opened process were considered for these specific amendments.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE899M01020/dd897bfe-de3d-4055-9c64-1c6b3309747c.pdf

iSERA Lifesciences Limited has received shareholder approval for a series of strategic resolutions following the conclusion of its postal ballot process through remote e-voting. The scrutinizer's report confirms that all seven proposed resolutions were passed with the requisite majority on May 21, 2026. The voting process was managed by MIPL via a designated e-voting platform, with participation from members holding shares as of the cut-off date of April 17, 2026.

Key Resolutions Approved

The resolutions covered significant corporate actions, including alterations to the company's capital structure and governance documents. Shareholders authorized an increase in the authorised share capital and the consequential alteration of the capital clause in the Memorandum of Association. Furthermore, the company approved the adoption of a new set of Memorandum of Association and Articles of Association, substituting the existing documents to align with the provisions of the Companies Act, 2013.

Acquisition and Capital Expansion

A major outcome of the ballot was the approval for the acquisition of up to 100% equity shareholding in iSERA Biological Limited, a target company, through a share swap. This included a specific resolution approving the related party transaction for the acquisition. To facilitate this, shareholders also authorized the issuance of equity shares via preferential issue on a private placement basis for consideration other than cash, specifically through the share swap mechanism. Additionally, the company received approval to enhance limits for making investments, giving loans, or providing securities under Section 186 of the Companies Act, 2013.

Voting Results Summary

The remote e-voting period commenced on April 22, 2026, and concluded on May 21, 2026. The scrutinizer's report details the voting patterns across different categories of shareholders. The resolutions received strong support, with the acquisition-related resolutions securing 100% of the votes polled. The table below summarizes the voting results for the key resolutions.

Shareholder Participation

The voting process saw participation from 31 members for the acquisition resolutions, while other resolutions saw participation ranging from 29 to 30 members. The Promoter and Promoter Group voted in favour of all resolutions, holding 4,930,000 shares. Public Non-Institutional shareholders also participated significantly, with 3,478,972 shares held. No physical postal ballots were dispatched, as per the relevant MCA Circulars, and all voting was conducted electronically. The records related to this postal ballot activity will be handed over to the authorised person of the company for safekeeping.